News for MacroGenics, Inc. (MGNX)

Shares of The AZEK Company Inc. AZEK rose sharply in today's pre-market trading after James Hardie Industries plc JHX announced plans to acquire the company for...

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating new LINNET Phase

**media[572458]**

MacroGenics' valuation has declined due to continued bad news in 2024, impacting market sentiment. Click here to find out why MGNX stock is a Buy.

ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. ( MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializi

Transaction Overview On December 31, 2024, ARMISTICE CAPITAL, LLC (Trades, Portfolio), a notable investment firm, executed a strategic stock transaction by acqu

On December 31, 2024, BB Biotech AG made a significant move in the biotechnology sector by acquiring an additional 5,114,399 shares of Macrogenics Inc. This tra

SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations of federal and state laws by c

Incyte (Nasdaq:INCY) today announced results from the Phase 3 POD1UM-304 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed

MacroGenix faces financial challenges with uncertain revenues and high expenses, leading to a 33% stock drop and limited appeal for new investors. Click to read.

Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications

ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. ( MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing

Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH

JMP has downgraded MacroGenics (MGNX) to market perform, calling the shares fairly valued and noting that the company's pipeline was in a holding pattern. Read more here.

Total Revenue: $110.7 million for Q3 2024, up from $10.4 million in Q3 2023.Net Income: $56.3 million for Q3 2024, compared to $17.6 million in Q3 2023.Researc

Lonza's Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC

MacroGenics' potential lies in Margenza, Lorigerlimab, and Enoblituzumab, but financial challenges persist. Read why I rate MGNX stock a strong sell for now.

Loading... Loading... Shares of Science Applications International Corporation SAIC declined 11% to $119.91 following first-quarter results. SAIC reported a 9...

Maryland-based biotechnology business Novavax, Inc. (NVAX) is up over 108% in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.